Senseonics partners Beta Bionics to link Eversense 365 with iLet
Senseonics Holdings has announced a strategic partnership with Beta Bionics to integrate its Eversense 365 continuous glucose monitor with Beta Bionics' iLet Bionic Pancreas automated insulin delivery system. The two NASDAQ-listed companies said they expect to complete development of the combined system in the fourth quarter of 2026, with a commercial launch planned for the same period, subject to testing, validation and applicable regulatory clearances.
The pairing brings together two technically distinct approaches to diabetes management. Eversense 365 is an implantable sensor, inserted by a healthcare provider and designed to measure glucose levels continuously for up to 365 days before requiring replacement. The iLet system is an automated insulin delivery platform that, the company says, does not require carbohydrate counting, instead determining and delivering insulin doses autonomously based on glucose readings.
The deal
Tim Goodnow, President and Chief Executive of Senseonics, said the collaboration builds on the company's earlier pump integration work and positions the Eversense platform to reach a wider population of people using automated insulin delivery. "We believe the combination of year-long glucose sensing and advanced automated insulin delivery offers compelling, differentiated benefits for people with diabetes," he said.
Senseonics describes Eversense 365 as the only long-term implantable CGM currently on the market, a positioning that distinguishes it from the dominant wearable patch-based systems made by Abbott (FreeStyle Libre) and Dexcom. Those competitors refresh their sensors every 10 to 15 days, making the annual-replacement model a meaningful differentiator for patients seeking reduced device burden. The iLet, meanwhile, competes in an automated insulin delivery segment that has grown rapidly following FDA clearances for a number of closed-loop systems over the past several years.
Market context
The automated insulin delivery market has attracted considerable attention from both medtech incumbents and pure-play diabetes specialists. Insulet's Omnipod 5, Medtronic's MiniMed 780G, and Tandem's Control-IQ are among the established systems, all of which currently rely on wearable CGM sensors for glucose input. A commercially launched Eversense-iLet integration would be the first pairing of an implantable CGM with a closed-loop AID system available to the general diabetes population, if it reaches the market on the stated timeline.
Investors will be watching the Q4 2026 window closely. The commercial launch is conditional on completing integration testing and satisfying applicable regulatory requirements, and Senseonics' forward-looking statements carried the standard caveats around partner coordination and regulatory process timelines. A real-world data study published in Diabetes Technology and Therapeutics in September 2026, cited by Senseonics, examined commercial users of the 365-day system, including those using it alongside the twiist AID system, and may provide a reference dataset for regulators and payers assessing the new integrated offer.
Beta Bionics listed on NASDAQ under the ticker BBNX. The iLet Bionic Pancreas received FDA clearance in 2023 and has been building its user community since. The addition of Eversense 365 as a supported CGM input would extend patient choice within the iLet ecosystem and could help Senseonics improve its commercial traction at a point when the company is still working to grow awareness and prescriber uptake of its implantable platform.